生物活性分子抑制剂 特异性抑制剂 激动剂 化合物库 重组蛋白 TMS (Synonyms: (E)-2,3′,4,5′-tetramethoxystilbene) 纯度: 99.21%
TMS ((E)-2,3′,4,5′-tetramethoxystilbene) 是一种选择性和竞争性 CYP1B1 抑制剂,IC50 为 6 nM,Ki 值为 3 nM。TMS 对 CYP1A1 (IC50=300 nM) 和 CYP1A2 (IC50=3.1 μM) 的抑制作用较小。TMS 是白藜芦醇的甲基化衍生物,具有抗癌活性。
TMS Chemical Structure
CAS No. : 24144-92-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥605 | In-stock | |
5 mg | ¥550 | In-stock | |
10 mg | ¥880 | In-stock | |
50 mg | ¥3300 | In-stock | |
100 mg | ¥5300 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
TMS 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Metabolism/Protease Compound Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Antioxidants Compound Library
- Oxygen Sensing Compound Library
- Targeted Diversity Library
生物活性 |
TMS ((E)-2,3′,4,5′-tetramethoxystilbene) is a selective and competitive CYP1B1 inhibitor with an IC50 of 6 nM and a Ki value of 3 nM. TMS shows a lesser extent inhibitory effect on CYP1A1 (IC5050[1][2][3]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||
体外研究 (In Vitro) |
TMS, an analogue of resveratrol, is considered to be a potential cancer preventive agent since it is a potent inhibitor of CYP1B1. To assess survival of MCF-7 cells exposed to 1 μM benzo[a]pyrene (BP), 1 μM BP+1 μM TMS and 1 μM BP+4 μM TMS, cells ae incubated for up to 72 h without a media change. Luminescence units from exposed cells, expressed as a percentage of luminescence units from solvent (DMSO)-treated cells at the same time intervals. In all exposure groups, cell viability remains >90% for the first 24 h, but by 72 h, cell survival drops to 60-70%[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
To determine the contribution of CYP1B1 in development of hypertension in spontaneously hypertensive rats (SHR), the effect of TMS is examined on in SHR and WKY rats. Systolic BP steadily increases in SHR from 4 weeks of age. Starting from 8 weeks of age, daily injections of TMS reduce systolic BP in SHR to levels observed at the beginning of the experiment (207±7 vs. 129±2 mmHg). Systolic BP is not altered in WKY injected with TMS or its vehicle (129±7 vs. 127±4 mmHg) [1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
300.35 |
||||||||||||||||
Formula |
C18H20O4 |
||||||||||||||||
CAS 号 |
24144-92-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (166.47 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
Cell viability is determined using the Cell Titer Glo Luminescent Cell Viability Assay. In brief, MCF-7 cells are seeded in 12-well plates (75 000 cells per well) in triplicate. Attached cells are exposed to 1 μM BP in the presence of 0, 1 or 4 μM TMS. At 4, 12, 24 or 72 h, RIPA Lysis Buffer (1x) is added to lyse the cells. A diluted sample of homogeneous cell lysate is transferred in duplicate to a 96-well plate and combined with an equivalent volume of Cell Titer Glo Luminescence. Luminescence measure using the Tropix 717 Microplate Luminometer. To examine viability of cells exposed to BP alone, the 72-h treatment is repeated twice, and for each experiment cells are assayed in triplicate. The values are expressed as % of the DMSO-alone solvent control[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [1] |
Mice[1] 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务